Actively Recruiting
Danicopan PMS in Korea
Led by AstraZeneca · Updated on 2026-04-17
8
Participants Needed
4
Research Sites
115 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
As part of a post-approval commitment, the Korean health authority requests a study to characterize safety and effectiveness in patients who are treated with Danicopan as an add-on to ravulizumab or eculizumab in normal clinical practice settings. This study is designed to assess the known safety profile or identify previously unsuspected adverse reactions and to evaluate the effectiveness of Danicopan under conditions of routine daily medical practice in Korea.
CONDITIONS
Official Title
Danicopan PMS in Korea
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients receiving Danicopan as add-on therapy to a C5 inhibitor (eculizumab or ravulizumab) for PNH in Korea
- Signed and dated informed consent provided by the patient or their legal representative
You will not qualify if you...
- Participation in any other interventional clinical trials during Danicopan treatment
- Use of Danicopan for off-label indications not approved in Korea
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Research Site
Busan, South Korea
Actively Recruiting
2
Research Site
Daegu, South Korea
Not Yet Recruiting
3
Research Site
Hwasun-gun, South Korea
Not Yet Recruiting
4
Research Site
Seoul, South Korea
Not Yet Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here